Arturo Galvani

Nerviano, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Stereoselective synthesis of 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one derivatives as PIM kinase inhibitors inspired from marine alkaloids.

Stereoselective synthesis of 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one derivatives as PIM kinase inhibitors inspired from marine alkaloids.

Journal: Chirality

Published: May 14, 2022

Identification of unprecedented ATP-competitive choline kinase inhibitors.

Identification of unprecedented ATP-competitive choline kinase inhibitors.

Journal: Bioorganic & medicinal chemistry letters

Published: April 27, 2021

Correction to Discovery of Entrectinib: A New 3-Aminoindazole as a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.

Correction to Discovery of Entrectinib: A New 3-Aminoindazole as a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.

Journal: Journal of medicinal chemistry

Published: August 20, 2019

Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515.

Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515.

Journal: ACS medicinal chemistry letters

Published: November 22, 2018

Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.

Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.

Journal: Investigational new drugs

Published: June 02, 2017

Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury.

Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury.

Journal: Molecular cancer therapeutics

Published: April 12, 2017

Establishment and genomic characterization of the new chordoma cell line Chor-IN-1.

Establishment and genomic characterization of the new chordoma cell line Chor-IN-1.

Journal: Scientific reports

Published: April 03, 2017

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.

Journal: Journal of medicinal chemistry

Published: March 23, 2016

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.

Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.

Journal: Molecular cancer therapeutics

Published: September 11, 2015

Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.

Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.

Journal: Journal of medicinal chemistry

Published: July 30, 2015

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.

Journal: British journal of cancer

Published: July 17, 2015

Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening.

Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening.

Journal: Oncotarget

Published: June 06, 2015

Showing 1-12 of 30

Last Updated: 09/26/2026